1. Home
  2. SBMT vs CHRS Comparison

SBMT vs CHRS Comparison

Compare SBMT & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silver Bow Mining Corp. Common Shares

SBMT

Silver Bow Mining Corp. Common Shares

N/A

Current Price

$6.81

Market Cap

184.0M

ML Signal

N/A

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.48

Market Cap

209.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBMT
CHRS
Founded
N/A
2010
Country
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
184.0M
209.8M
IPO Year
2026
2014

Fundamental Metrics

Financial Performance
Metric
SBMT
CHRS
Price
$6.81
$1.48
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.51
AVG Volume (30 Days)
77.3K
707.2K
Earning Date
N/A
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
472.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$73.08
Revenue Next Year
N/A
$30.94
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.75
$0.81
52 Week High
$8.98
$2.62

Technical Indicators

Market Signals
Indicator
SBMT
CHRS
Relative Strength Index (RSI) 36.87 43.92
Support Level $5.90 $1.38
Resistance Level $6.60 $1.42
Average True Range (ATR) 0.38 0.07
MACD 0.06 -0.00
Stochastic Oscillator 15.82 17.86

Price Performance

Historical Comparison
SBMT
CHRS

About SBMT Silver Bow Mining Corp. Common Shares

Silver Bow Mining Corp is engaged in the acquisition, exploration, and development of mineral resource properties in Butte, Montana, USA. The Company's primary business objective is to identify and evaluate prospective properties with the potential for future extraction and commercialization.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: